Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Burfiralimab in Moderate to Severe COVID-19
NCT04679350Phase 2Terminated
- Sponsor
- ImmuneMed Inc.
- Start
- Mar 2021
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of burfiralimab in coronavirus disease 2019 (COVID-19), sponsored by ImmuneMed Inc.. Started Mar 2021; status: terminated.
02
Drugs
burfiralimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04679350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04679350.